MEKK3 and survivin expression in cervical cancer: Association with clinicopathological factors and prognosis

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 13, 2014, Pages 5271-5276

  Cao, Xue Quan ^a   Lu, Hong Sheng ^a   Zhang, Ling ^a   Chen, Li Li ^a   Gan, Mei Fu ^b  

^a Central Hospital of Taizhou   (China)

^b TAIZHOU HOSPITAL OF ZHEJIANG PROVINCE   (China)

Author keywords

Cervical cancer; MEKK3; Prognosis; Survivin

Indexed keywords

BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; MAP3K3 PROTEIN, HUMAN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 3;

ADULT; AGED; APOPTOSIS; FEMALE; GENETICS; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; UTERINE CERVICITIS; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR;

ADULT; AGED; APOPTOSIS; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MAP KINASE KINASE KINASE 3; MIDDLE AGED; PROGNOSIS; RNA, MESSENGER; UTERINE CERVICAL NEOPLASMS; UTERINE CERVICITIS;

EID: 84905392758     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.13.5271     Document Type: Article

References (31)

1. Altieri DC (2003). Survivin in apoptosis control and cell cycle regulation in cancer. Prog Cell Cycle Res, 5, 447-52.
2. Blank JL, Gerwins P, Johnson GL, et al (1996). Molecular cloning of mitogen-activated protein/EPK kinase kinase (MEKK)2 and 3. Regulation of sequential phosphorylation pathways involving mitogen-activated protein kinase and c-Jun kinase. J Biol Chem, 271, 5361-8.
3. Bongiovanni L, Romanucci M, Malatesta D, et al (2014). Survivin and related proteins in canine mammary tumors: immunohistochemical expression. Vet Pathol, 31. [Epub ahead of print].
4. Cadron I, Van Gorp T, Amant F, et al (2007). Chemotherapy for recurrent cervical cancer. Gynecol Oncol, 107, 113-8.
5. Caffarel MM, Coleman N (2014). Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma. J Pathol, 232, 386-90.
6. Chang L, Karin M (2001). Mammalian MAP kinase signalling cascades. Nature, 410, 37-40.
7. Chen HA, Su CM, Hsieh HY, et al (2014). Clinical significance of survivin expression in patients with urothelial carcinoma. Dis Markers. 574985. [Epub 2014 Feb 5].
8. Craig EA, Stevens MV, Vaillancourt RR, et al (2008). MAP3Ks as central regulators of cell fate during development.Developmental Dynamics, 237, 3102-14.
9. Deng Y, Yang J, McCarty M, et al (2007). MEKK3 is required for endothelium function but is not essential for tumor growth and angiogenesis. Am J Physiol Cell Physiol, 293, 1404-11.
10. Gao F, Zhang Y, Yang F, et al (2014). Survivin promotes the invasion of human colon carcinoma cells by regulating the expression of MMP 7. Mol Med Rep, 9, 825-30.
11. Gho GS, Ahn TS (2011). Expression of the surviving-2B splice variant related to the progression of colorectal carcinomas. J Korean Surg Soc, 80, 404-11.
12. Hasan R, Sharma R, Saraya A, et al (2014). Mitogen activated protein kinase kinase kinase 3 (MAP3K3/MEKK3) overexpression is an early event in esophageal tumorigenesis and is a predictor of poor disease prognosis. BMC Cancer, 14, 2.
13. Indarti J, Aziz MF, Suryawati B, et al (2013). Scoring system and management algorithm assessing the role of survivin expression in predicting progressivity of HPV infections in precancerous cervical lesions. Asian Pac J Cancer Prev. 14, 1643-7.
14. Johnson GL, Lapadat R (2002). Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science, 98, 1911-2.
15. Karami H, Baradaran B, Esfahani A, et al (2013). siRNA-mediated silencing of survivin inhibits proliferation and enhances etoposide chemosensitivity in acute myeloid leukemia cells. Asian Pac J Cancer Prev, 14, 7719-24.
16. Karimi ZM, Behtash N, Chiti Z, et al (2009). Cervical cancer and HPV vaccines in d eveloping coutries. Asian Pac J Cancer Prev, 10, 969-74.
17. Kazuhiro N, Adam J, Kimple1, et al (2010). PB1 domain interaction of p62/Sequestosome1 and MEKK3regulates NF-κB activation. J Biol Chem, 285, 2077-89.
18. Kitamura Hn in, Torigoe T, Honma I, et al (2006). Expression and antigenicity of Survivin, ahibitor of apoptosis family number, in bladder cancer: implication for specific immunotherapy. Urology, 67, 955-9.
19. Kumar A, Raziuddin M, Ralhan R, et al (2007). Discovery of deregulation of zinc homeostasis and its associated genes in esophageal squamous cell carcinoma usingicr cDNA m oarray. Int J Cancer, 120, 230-42.
20. LaCasse EC, Mahoney DJ, Cheung HH, et al (2008). IAP-targeted therapies for cancer. Oncogene, 27, 6252-75.
21. Li F, Ambrosini G, Chu EY, et al (1998). Control of apoptosis and mitotic spindle checkpoint by survivin. Nature, 396, 580-4.
22. Lu H, Gan M, Zhang G, et al (2010). Expression of survivin, caspase-3 and p53 in cervical cancer assessed by tissue microarray: correlation with clinicopathology and prognosis. Eur J Gynaecol Oncol, 31, 662-6.
23. Samanta AK, Huang HJ, Le XF, et al (2009). MEKK3 expression correlates with nuclear factor kappa B activity and with expression of anti-apoptotic genes in serous ovarian carcinoma. Cancer, 115, 3897-908.
24. Samanta AK, Huang HJ, Liao WS, et al (2004). Overexpression of MEKK3 confers resistance to apoptosis through activation of NF-κB. J Biol Chem, 279, 7576-83.
25. Srivastava K, Srivastava A, Mittal B (2012). Survivin promoter-31G/C (rs9904341) polymorphism and cancer susceptibility: a meta-analysis. Molecular Biology Reports, 39, 1509-16.
26. Sun WJ, Li HX, YU Y, et al (2009). MEKK3 is required for lysophosphatidic acid-induced NF-κB activation.Cell Signal, 21, 1488-94.
27. Wand H, Xi X, Kong X, et al (2004). The expression and significance of Survivin mRNA in urinary bladder carcinomas. J Cancer Res Clin Oncol, 130, 487-90.
28. Wu SF, Zhang JW, Qian WY, et al (2012). Altered expression of survivin, Fas and FasL contributed to cervical cancer development and metastasis. Eur Rev Med Pharmacol Sci, 16, 2044-50.
29. Xu BE, Stippec S, Lenertz L, et al (2004). WNK1 activates ERK5 by an MEKK2/3-dependent mechanism. J Biol Chem, 279, 7826-31.
30. Yang J, Lin Y, Guo Z, et al (2001). The essential role of MEKK3 in TNF-induced NF-κB activation. Nat Immunol, 2, 620-4.
31. YU L, Wang X, Langley RR, et al (2006). The role of MEKK3 in osteosarcoma invasion and metastasis. Proc Amer Assoc Cancer Res, 47, 207-10.